{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:13:26Z","timestamp":1792674806058,"version":"4.5.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Tumor-induced osteomalacia (TIO) is a rarely diagnosed disorder presenting with bone pain, fractures, muscle weakness, and moderate-to-severe hypophosphatemia resulting from fibroblast growth factor 23-mediated renal phosphate wasting. Tumors secreting fibroblast growth factor 23 are often small and difficult to find with conventional imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We studied the utility of 68Ga-DOTA-octreotate (DOTATATE) somatostatin receptor positron emission tomography (PET)\/computed tomography (CT) imaging in the diagnosis of TIO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting:<\/jats:title>\n                    <jats:p>A multicenter case series was conducted at tertiary referral hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Six patients with TIO diagnosed between 2003 and 2012 in Australia were referred for DOTATATE PET imaging. We reviewed the clinical history, biochemistry, imaging characteristics, histopathology, and clinical outcome of each patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Each case demonstrated delayed diagnosis despite severe symptoms. DOTATATE PET\/CT imaging demonstrated high uptake and localized the tumor with confidence in each case. After surgical excision, there was resolution of clinical symptoms and serum phosphate, except in one patient who demonstrated residual disease on PET\/CT. All tumors demonstrated high somatostatin receptor subtype 2 cell surface receptor expression using immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with TIO, DOTATATE PET\/CT can successfully localize phosphaturic mesenchymal tumors and may be a practical first step in functional imaging for this disorder. Serum phosphate should be measured routinely in patients with unexplained muscle weakness, bone pain, or stress fractures to allow earlier diagnosis of TIO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2012-3642","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T17:42:57Z","timestamp":1357666977000},"page":"687-694","source":"Crossref","is-referenced-by-count":102,"title":["Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET\/CT"],"prefix":"10.1210","volume":"98","author":[{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"first","affiliation":[{"name":"Cancer Genetics Unit (R.J.C.-B.), Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia"},{"name":"University of Sydney (R.J.C.-B., A.J.G.), Sydney, New South Wales 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[{"name":"Molecular Imaging (M.S.H., R.J.H.), Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne 3002, Victoria, Australia"},{"name":"Department of Medicine (M.S.H., P.R.E., R.J.H.), University of Melbourne, Melbourne, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Duncan","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women's Hospital (E.D.), Brisbane, Queensland 4029, Australia"},{"name":"The University of Queensland Diamantina Institute Brisbane (E.D.), Queensland 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Wen","family":"Sim","sequence":"additional","affiliation":[{"name":"Western Centre for Health Research and Education (I.-W.S., P.R.E.), Western Health, Melbourne, Victoria 3008, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darnell","sequence":"additional","affiliation":[{"name":"Gosford Hospital (D.D.), Gosford, New South Wales 2250, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Clarkson","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology (A.C., A.J.G.), Royal North Shore Hospital, Sydney, New South Wales 2065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Wong","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital (T.W.), Hobart, Tasmania 7000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (J.P.W.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia"},{"name":"School of Medicine and Pharmacology (J.P.W.), University of Western Australia, Crawley, Western Australia 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[{"name":"University of Sydney (R.J.C.-B., A.J.G.), Sydney, New South Wales 2006, Australia"},{"name":"Department of Anatomical Pathology (A.C., A.J.G.), Royal North Shore Hospital, Sydney, New South Wales 2065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Department of Medicine (M.S.H., P.R.E., R.J.H.), University of Melbourne, Melbourne, Victoria 3010, Australia"},{"name":"Western Centre for Health Research and Education (I.-W.S., P.R.E.), Western Health, Melbourne, Victoria 3008, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Molecular Imaging (M.S.H., R.J.H.), Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne 3002, Victoria, Australia"},{"name":"Department of Medicine (M.S.H., P.R.E., R.J.H.), University of Melbourne, Melbourne, Victoria 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071617481195200_B1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","author":"Jan de Beur","year":"2005","journal-title":"JAMA"},{"key":"2020071617481195200_B2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc070347","article-title":"Radiofrequency ablation of a tumor causing oncogenic osteomalacia","volume":"357","author":"Hesse","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071617481195200_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am J Surg Path"},{"key":"2020071617481195200_B4","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071617481195200_B5","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1210\/jc.2002-021919","article-title":"Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia","volume":"88","author":"Nelson","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617481195200_B6","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071617481195200_B7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1210\/jcem.86.2.7408","article-title":"The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting","volume":"86","author":"White","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617481195200_B8","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617481195200_B9","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Rel Cancer"},{"key":"2020071617481195200_B10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jan de Beur","year":"2002","journal-title":"Lancet"},{"key":"2020071617481195200_B11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","article-title":"Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT scan for the diagnosis and follow-up in one case","volume":"36","author":"Dupond","year":"2005","journal-title":"Bone"},{"key":"2020071617481195200_B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4158\/EP10151.OR","article-title":"Tumor-induced osteomalacia: a single center experience","volume":"17","author":"Jagtap","year":"2011","journal-title":"Endocr Pract"},{"key":"2020071617481195200_B13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S8756-3282(99)00170-2","article-title":"Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia","volume":"25","author":"Fukumoto","year":"1999","journal-title":"Bone"},{"key":"2020071617481195200_B14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2169\/internalmedicine.47.0745","article-title":"Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23","volume":"47","author":"Nasu","year":"2008","journal-title":"Intern Med"},{"key":"2020071617481195200_B15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","article-title":"Selective venous catheterization for the localization of phosphaturic mesenchymal tumors","volume":"26","author":"Andreopoulou","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020071617481195200_B16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-07-0779","article-title":"Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling","volume":"158","author":"van Boekel","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071617481195200_B17","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","article-title":"Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data","volume":"28","author":"Hofmann","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2020071617481195200_B18","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","article-title":"DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals","volume":"30","author":"Wild","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020071617481195200_B19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2020071617481195200_B20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1359\/jbmr.060909","article-title":"Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography","volume":"22","author":"Hesse","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071617481195200_B21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00259-008-0755-8","article-title":"(68)Ga-DOTANOC PET\/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia","volume":"35","author":"von Falck","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020071617481195200_B22","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2010-0543","article-title":"Tumor-induced hypophosphatemic rickets in an adolescent boy\u2014clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue","volume":"95","author":"Haeusler","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 1","key":"2020071617481195200_B23","first-page":"79","article-title":"2000 Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram","volume":"37","author":"Barth","journal-title":"Ann Clin Biochem"},{"key":"2020071617481195200_B24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"key":"2020071617481195200_B25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.107.040378","article-title":"Processing of generator-produced 68Ga for medical application","volume":"48","author":"Zhernosekov","year":"2007","journal-title":"J Nucl Med"},{"key":"2020071617481195200_B26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/cbr.2011.1073","article-title":"Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131","volume":"27","author":"De Decker","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"2020071617481195200_B27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China. Report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2020071617481195200_B28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bone.2006.07.027","article-title":"A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery","volume":"40","author":"Elston","year":"2007","journal-title":"Bone"},{"key":"2020071617481195200_B29","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/2\/687\/13652872\/jcem0687.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/2\/687\/13652872\/jcem0687.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:39:38Z","timestamp":1594942778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/2\/687\/2833179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-3642","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,1]]}}}